Biotech, Medicine, Prostate Cancer

Dendreon May Open Atlanta Plant

Eric Hal Schwartz 7/17/09

Dendreon, the Seattle-based cancer drug developer, may open a new manufacturing plant in Georgia, according to a report in the Atlanta Business Chronicle. Dendreon’s product, a new drug to treat prostate cancer, is being reviewed for approval by the FDA. Xconomy has written about Dendreon’s limited manufacturing before. The possible plant could cost $80 million and create more than 300 jobs in Atlanta. Currently, Dendreon has a commercial manufacturing plant in Morris Plains, NJ.

Eric Hal Schwartz is an intern in Xconomy's Seattle office. He can be reached at eschwartz@xconomy.com.